Jihua Liu resumes & CV records
Resumes
Jihua Liu, 58Whittier, CA
Jihua Liu Phones & Addresses
Whittier, CA
Montebello, CA
San Marcos, CA
Bountiful, UT
Salt Lake City, UT
Oceanside, CA
North Salt Lake, UT
Los Angeles, CA
933 Mira Lago Way, San Marcos, CA 92078 801-7979121
Mentions for Jihua Liu
Publications & IP owners
Us Patents
Methods And Compositions Involving Protein Kinase C-Delta
US Patent:
2008024, Oct 9, 2008
Filed:
Jul 22, 2005
Appl. No.:
11/658191
Inventors:
Jihua Liu - Salt Lake City UT, US
David Durrant - Richmond VA, US
David Durrant - Richmond VA, US
International Classification:
A61K 31/70
C12Q 1/48
A61P 43/00
A61K 31/69
C12Q 1/48
A61P 43/00
A61K 31/69
US Classification:
514 44, 435 15, 514 64
Abstract:
Disclosed are methods and compositions relating to the use of PKC-δ activators in the treatment of disease.
Phospholipid Scramblase 3
US Patent:
2006017, Aug 3, 2006
Filed:
Mar 15, 2004
Appl. No.:
10/548329
Inventors:
Qiang Dai - Salt Lake City UT, US
Jun Chen - Salt Lake City UT, US
Jihua Liu - Salt Lake City UT, US
Jun Chen - Salt Lake City UT, US
Jihua Liu - Salt Lake City UT, US
International Classification:
A61K 48/00
C12Q 1/68
C07H 21/02
C12Q 1/68
C07H 21/02
US Classification:
514044000, 435006000, 536023100
Abstract:
Phospholipid scramblase 3 (PLS3) is a newly recognized member of a family of proteins responsible for phospholipid translocation between two lipid compartments. A novel isoform of PLS3 is identified and characterized herein. The function of PLS3 in mitochondria was disrupted, yielding an inactive mutant PLS3(F258V). Cells transfected with PLS3(F258V) exhibited reduced proliferative capacity that was unaffected by the presence of NaN. PLS3(F258V)-expressing cells exhibit abnormal mitochondrial metabolism and structure and were associated with decreased sensitivity to UV- and tBid-induced apoptosis, and diminished translocation of cardiolipin to the outer mitochondrial membrane. Cells transfected with wild-type PLS3 displayed increased sensitivity to apoptosis and enhanced cardiolipin translocation. These studies identify PLS3 as a regulator of mitochondrial structure and respiration, and cardiolipin transport in apoptosis.
Methods And Compositions For Treating Malignant Tumors Associated With Kras Mutation
US Patent:
2022027, Sep 1, 2022
Filed:
May 18, 2022
Appl. No.:
17/664032
Inventors:
- Osaka, JP
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
International Classification:
C12N 15/113
A61K 9/127
A61K 31/713
A61K 31/7105
A61K 9/127
A61K 31/713
A61K 31/7105
Abstract:
This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
Pkm2 Modulators And Methods For Their Use
US Patent:
2021000, Jan 7, 2021
Filed:
Jul 15, 2020
Appl. No.:
16/930254
Inventors:
- Cambridge MA, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US
International Classification:
C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
A61P 11/00
A61P 43/00
A61P 35/00
A61K 31/4155
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
A61P 11/00
A61P 43/00
A61P 35/00
A61K 31/4155
Abstract:
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Pkm2 Modulators And Methods For Their Use
US Patent:
2020010, Apr 9, 2020
Filed:
Sep 26, 2019
Appl. No.:
16/584912
Inventors:
- Lehi UT, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US
International Classification:
C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
Abstract:
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Methods And Compositions For Treating Malignant Tumors Associated With Kras Mutation
US Patent:
2019036, Dec 5, 2019
Filed:
Aug 14, 2019
Appl. No.:
16/540973
Inventors:
- Osaka, JP
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
International Classification:
C12N 15/113
A61K 9/127
A61K 31/713
A61K 9/127
A61K 31/713
Abstract:
This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
Methods And Compositions For Treating Malignant Tumors Associated With Kras Mutation
US Patent:
2018000, Jan 4, 2018
Filed:
Jun 28, 2017
Appl. No.:
15/636528
Inventors:
- Osaka, JP
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
Jihua Liu - San Marcos CA, US
Li Wang - San Diego CA, US
Bharat Majeti - San Diego CA, US
Roger Adami - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
International Classification:
C12N 15/113
A61K 9/127
A61K 31/713
A61K 9/127
A61K 31/713
Abstract:
This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
Methods For Malignant Tumors With Rnai Molecules Targeted To Hsp47
US Patent:
2017021, Aug 3, 2017
Filed:
Apr 17, 2017
Appl. No.:
15/489650
Inventors:
- Osaka, JP
Yasuaki Tamura - Hokkaido, JP
Kenjirou Minomi - Osaka, JP
Bharat Majeti - San Diego CA, US
Jihua Liu - San Marcos CA, US
Wenbin Ying - San Diego CA, US
Yasuaki Tamura - Hokkaido, JP
Kenjirou Minomi - Osaka, JP
Bharat Majeti - San Diego CA, US
Jihua Liu - San Marcos CA, US
Wenbin Ying - San Diego CA, US
International Classification:
C12N 15/113
Abstract:
This invention provides methods for preventing, treating or ameliorating one or more symptoms of a malignant tumor in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising RNAi molecules, where the RNAi molecules can be active in reducing expression of Hsp47.
Possible Relatives
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.